SPC
IRWD icon

Slate Path Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Slate Path Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,640,000
Closed -$27.2M – 31
2020
Q2 		$27.2M Buy
2,640,000
+1,300,000
+97% +$13.3M 1.61% 14
2020
Q1 		$13.5M Buy
+1,340,000
New +$15.7M 1.04% 13

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Slate Path Capital's IRWD Position: Q3 2020 in Review

Slate Path Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2020, closing a stake of 2,640,000 shares — an estimated $27.2M sold.

Slate Path Capital first reported a position in IRWD in Q1 2020 and held it in 2 quarters. The position peaked at $27.2M in Q2 2020. 190 funds tracked by Wall St. Rank hold IRWD as of Q3 2020.

  • Slate Path Capital reported no remaining Ironwood Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Slate Path Capital sold 2,640,000 Ironwood Pharmaceuticals shares in Q3 2020, an estimated $27.2M.
  • Slate Path Capital first reported a position in Ironwood Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Slate Path Capital's Ironwood Pharmaceuticals position peaked at $27.2M in Q2 2020.
  • 190 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2020.

Based on Slate Path Capital's 13F filing for Q3 2020, filed 16 Nov 2020.